Previous 10 | Next 10 |
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer...
ARK Invest has published their main investment themes for each year since 2017, including numerical projections for how these themes will grow and outperform. I checked how accurate their 2017 projections were over the last five years and was surprised by what I found. I also look...
VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose...
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics , a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will...
Verve Therapeutics (NASDAQ:VERV) appointed Allison Dorval as its new CFO; Ms. Dorval joins Verve from Voyager Therapeutics and brings 20+ years of leadership experience in finance, accounting, financial reporting and investor relations. "Her extensive experience leading finance func...
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics , Inc., (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Allison Dorval has been appointed as chief fin...
Gainers: Pasithea Therapeutics (NASDAQ:KTTA) +257%, Petros Pharmaceuticals (NASDAQ:PTPI) +73%, Gracell Biotechnologies (NASDAQ:GRCL) +64%, iSpecimen (NASDAQ:ISPC) +43%, Qualigen Therapeutics (NASDAQ:QLGN) +33%. Losers: Longeveron (NASDAQ:LGVN) -36%...
Verve Therapeutics (NASDAQ:VERV): Q3 GAAP EPS of -$0.47 beats by $0.05. Cash, cash equivalents and marketable securities were $389.2M as of September 30, 2021 Press Release For further details see: Verve Therapeutics EPS beats by $0.05
VERVE-101 Preclinical Data Announced at TIDES 2021 Demonstrated Potent, Durable PCSK9 Protein and LDL-C Reductions, Supporting Planned Clinical Initiation in 2022 New Preclinical Data from ANGPTL3 Program Highlight Potent Editing with Proprietary GalNAc-LNP Delivery in a Novel N...
ANGPTL3 Base Editor Delivered via Internally Developed GalNAc-LNPs Potently Reduced Blood ANGPTL3 Protein by 94-97% in a Novel NHP Model of Homozygous Familial Hypercholesterolemia GalNAc-LNP Delivery of ANGPTL3 Base Editor Led to Potent Editing in both LDLR-Deficient and No...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...